Patents by Inventor Joe W. Gray
Joe W. Gray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120214829Abstract: Herein is described the use of a collection of 50 breast cancer cell lines to match responses to 77 conventional and experimental therapeutic agents with transcriptional, proteomic and genomic subtypes found in primary tumors. Almost all compounds produced strong differential responses across the cell lines produced responses that were associated with transcriptional and proteomic subtypes and produced responses that were associated with recurrent genome copy number abnormalities. These associations can now be incorporated into clinical trials that test subtype markers and clinical responses simultaneously.Type: ApplicationFiled: February 21, 2012Publication date: August 23, 2012Applicant: The Regents of the University of CaliforniaInventors: Paul T. Spellman, Joe W. Gray, Anguraj Sadanandam, Laura M. Heiser, William J. Gibb, Wen-Lin Kuo, Nicholas J. Wang
-
Publication number: 20120178104Abstract: A signature of a condition of a live cell is established in an assay that allows distribution of the receptors on the cell surface in response to binding a ligand. The receptors can be optically detected and quantified to provide a value for the condition, Test drugs can be screened for therapeutic potential in the assay: a potentially efficacious drug is identified by an ability to modulate an established signature. The receptor distribution signature can be corroborated with an mRNA expression profile of several genes, indicating, for example, metastasis.Type: ApplicationFiled: July 29, 2011Publication date: July 12, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Khalid S. Salaita, Pradeep M. Nair, Debopriya Das, Joe W. Gray, John T. Groves
-
Patent number: 8198254Abstract: Amplification of the ANXA9 gene in human chromosomal region 1q21 in epithelial cancers indicates a likelihood of both in vivo drug resistance and metastasis, and serves as a biomarker indicating these aspects of the disease. ANXA9 can also serve as a therapeutic target. Interfering RNAs (iRNAs) (such as siRNA and miRNA) and shRNA adapted to inhibit ANXA9 expression, when formulated in a therapeutic composition, and delivered to cells of the tumor, function to treat the epithelial cancer.Type: GrantFiled: March 26, 2009Date of Patent: June 12, 2012Assignee: The Regents of the University of CaliforniaInventors: Zhi Hu, Wen-Lin Kuo, Richard M. Neve, Joe W. Gray
-
Patent number: 8173602Abstract: This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biological sample from an animal (e.g. a human patient); (ii) detecting the level of CYP24 within the biological sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biological sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal.Type: GrantFiled: December 8, 2009Date of Patent: May 8, 2012Assignee: The Regents of the University of CaliforniaInventors: Donna G. Albertson, Daniel Pinkel, Colin Collins, Joe W. Gray, Bauke Ylstra
-
Publication number: 20120077694Abstract: Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers.Type: ApplicationFiled: September 23, 2011Publication date: March 29, 2012Applicant: The Regents of the University of CaliforniaInventors: Joe W. Gray, Jane Fridlyand, Richard Neve, Paul Spellman, Koei Chin, Zhi Hu, Frederic Waldman
-
Patent number: 8101370Abstract: The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases.Type: GrantFiled: May 27, 2008Date of Patent: January 24, 2012Assignees: The Regents of the University of California, The Hospital for Sick ChildrenInventors: Joe W. Gray, Colin Conrad Collins, Soo-in Hwang, Tony Godfrey, David Kowbel, Johanna Rommens
-
Patent number: 8021837Abstract: Disclosed are new methods comprising the use of in situ hybridization to detect abnormal nucleic acid sequence copy numbers in one or more genomes wherein repetitive sequences that bind to multiple loci in a reference chromosome spread are either substantially removed and/or their hybridization signals suppressed. The invention termed Comparative Genomic Hybridization (CGH) provides for methods of determining the relative number of copies of nucleic acid sequences in one or more subject genomes or portions thereof (for example, a tumor cell) as a function of the location of those sequences in a reference genome (for example, a normal human genome). The intensity(ies) of the signals from each labeled subject nucleic acid and/or the differences in the ratios between different signals from the labeled subject nucleic acid sequences are compared to determine the relative copy numbers of the nucleic acid sequences in the one or more subject genomes as a function of position along the reference chromosome spread.Type: GrantFiled: February 24, 2006Date of Patent: September 20, 2011Assignee: The Regents of the University of CaliforniaInventors: Daniel Pinkel, Joe W Gray, Anne Kallioniemi, Ollie-Pekka Kallioniemi, Frederic Waldman, Masaru Sakamoto
-
Patent number: 8003376Abstract: The invention provides methods and devices for detecting the presence of one or more target analytes in a sample employing a channel having affixed therein one or more binding partners for each target analyte. Assays are carried out by transporting the sample through the channel to each successive binding partner so that target analyte present in said sample binds to the corresponding binding partner. The sample is then transported beyond the binding partner(s), followed by detection of any target analyte bound to each binding partner. In one embodiment, binding efficiency is increased by the use of segmented transport, wherein a first bolus or bubble of a fluid that is immiscible with the sample precedes the sample during transport and a second bolus or bubble of a fluid that is immiscible with the sample follows the sample. Many configurations are possible for the device of the invention.Type: GrantFiled: May 5, 2010Date of Patent: August 23, 2011Assignee: The Regents of the University of CaliforniaInventors: Mack J. Fulwyler, Joe W. Gray
-
Publication number: 20110183336Abstract: Methods of-identifying a basal or luminal phenotype of a cell, comprising detecting expression of one or more of a set of predictive biomarker genes or proteins that identify the cell as having a basal or luminal cancer subtype and compositions for treating identified basal or luminal cancers.Type: ApplicationFiled: April 26, 2010Publication date: July 28, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: JOE W. GRAY, DEBOPRIYA DAS, WEN-LIN KUO, NICHOLAS J. WANG, RICHARD M. NEVE, PAUL T. SPELLMAN, JANE FRIDLYAND, KOEI CHIN, ZHI HU
-
Publication number: 20100285023Abstract: This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biological sample from an animal (e.g. a human patient); (ii) detecting the level of CYP24 within the biological sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biological sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal.Type: ApplicationFiled: December 8, 2009Publication date: November 11, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Donna G. Albertson, Daniel Pinkel, Colin Collins, Joe W. Gray, Bauke Ylstra
-
Publication number: 20100279899Abstract: The invention provides methods and devices for detecting the presence of one or more target analytes in a sample employing a channel having affixed therein one or more binding partners for each target analyte. Assays are carried out by transporting the sample through the channel to each successive binding partner so that target analyte present in said sample binds to the corresponding binding partner. The sample is then transported beyond the binding partner(s), followed by detection of any target analyte bound to each binding partner. In one embodiment, binding efficiency is increased by the use of segmented transport, wherein a first bolus or bubble of a fluid that is immiscible with the sample precedes the sample during transport and a second bolus or bubble of a fluid that is immiscible with the sample follows the sample. Many configurations are possible for the device of the invention.Type: ApplicationFiled: May 5, 2010Publication date: November 4, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Mack J. Fulwyler, Joe W. Gray
-
Publication number: 20100279876Abstract: The present invention provides a method of detecting nucleotide sequence differences between two nucleic acid samples. The method employs a comparative genomic hybridization (CGH) technique to analyze the sequence differences between the samples. This method permits the identification of small sequence differences (e.g., sequence divergence of 1% or less) in nucleic acid samples of high complexity (e.g., an entire genome).Type: ApplicationFiled: March 17, 2009Publication date: November 4, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Donna G. Albertson, Daniel Pinkel, Jane Fridyland, Bing Huey, Antoine Snijders, Joe W. Gray, Anne Kallioniemi, Olli-Pekka Kallioniemi, Frederic Waldman
-
Patent number: 7811986Abstract: The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases.Type: GrantFiled: July 22, 2008Date of Patent: October 12, 2010Assignees: The Regents of The University of California, The Hospital for Sick ChildrenInventors: Joe W. Gray, Colin Conrad Collins, Soo-in Hwang, Tony Godfrey, David Kowbel, Johanna Rommens
-
Publication number: 20100255602Abstract: A method of analyzing biological material by exposing the biological material to a recognition element, that is coupled to a mass tag element, directing an ion beam of a mass spectrometer to the biological material, interrogating at least one region of interest area from the biological material and producing data, and distributing the data in plots.Type: ApplicationFiled: May 26, 2010Publication date: October 7, 2010Inventors: James S. Felton, Kuang Jen J. Wu, Mark G. Knize, Kristen S. Kulp, Joe W. Gray
-
Patent number: 7776536Abstract: The present invention provides methods of determining relative copy number of target nucleic acids and precise mapping of chromosomal abnormalities associated with disease. The methods of the invention use target nucleic acids immobilized on a solid surface, to which a sample comprising two sets of differentially labeled nucleic acids are hybridized. The hybridization of the labeled nucleic acids to the solid surface is then detected using standard techniques.Type: GrantFiled: March 29, 2007Date of Patent: August 17, 2010Assignee: The Regents of the University of CaliforniaInventors: Daniel Pinkel, Donna Albertson, Joe W. Gray
-
Publication number: 20100204125Abstract: The present invention provides new probes for the detection of chromosomal alterations associated with cancer, particularly ovarian cancer. The probes bind selectively with target nucleic acid sequences at 3q26.Type: ApplicationFiled: March 1, 2010Publication date: August 12, 2010Applicants: The Regents of the University of California, Board of Regents, The University of Texas SystemInventors: Laleh Shayesteh, Joe W. Gray, Gordon B. Mills, Yiling Lu
-
Patent number: 7741104Abstract: The invention provides methods and devices for detecting the presence of one or more target analytes in a sample employing a channel having affixed therein one or more binding partners for each target analyte. Assays are carried out by transporting the sample through the channel to each successive binding partner so that target analyte present in said sample binds to the corresponding binding partner. The sample is then transported beyond the binding partner(s), followed by detection of any target analyte bound to each binding partner. In one embodiment, binding efficiency is increased by the use of segmented transport, wherein a first bolus or bubble of a fluid that is immiscible with the sample precedes the sample during transport and a second bolus or bubble of a fluid that is immiscible with the sample follows the sample. Many configurations are possible for the device of the invention.Type: GrantFiled: December 1, 2005Date of Patent: June 22, 2010Assignee: The Regents of the University of CaliforniaInventors: Mack J Fulwyler, Joe W Gray
-
Patent number: 7728287Abstract: A method of analyzing biological material by exposing the biological material to a recognition element, that is coupled to a mass tag element, directing an ion beam of a mass spectrometer to the biological material, interrogating at least one region of interest area from the biological material and producing data, and distributing the data in plots.Type: GrantFiled: March 1, 2007Date of Patent: June 1, 2010Assignee: Lawrence Livermore National Security, LLCInventors: James S. Felton, Kuang Jen J. Wu, Mark G. Knize, Kristen S. Kulp, Joe W. Gray
-
Patent number: 7670767Abstract: The present invention provides new probes for the detection of chromosomal alterations associated with cancer, particularly ovarian cancer. The probes bind selectively with target nucleic acid sequences at 3q26.Type: GrantFiled: August 4, 1997Date of Patent: March 2, 2010Assignees: The Regents of the University of California, Board of Regents, The University of Texas SystemInventors: Laleh Shayesteh, Joe W. Gray, Gordon B. Mills, Yiling Lu
-
Publication number: 20100028259Abstract: The present invention provides, for the first time, the finding that organic cation transporters (OCTs) are major determinants of the anticancer activity of platinum-based drugs such as oxaliplatin, and therefore have clinical significance for selecting oxaliplatin as the preferred therapy for a cancer that expresses one or more OCTs, such as colorectal cancer or liver cancer. In addition, the OCT genotype can also be used to predict oxaliplatin response or to select therapy. The present invention also provides methods of treating or inhibiting cancers that expresses one or more OCTs by administering a therapeutically effective amount of a platinum-based drug such as an oxaliplatin analog having an organic non-leaving group with an increased size. The present invention further provides methods of sensitizing a therapy resistant cancer to a platinum-based drug such as oxaliplatin by administering a therapeutically effective amount of a nucleic acid encoding an OCT.Type: ApplicationFiled: April 18, 2007Publication date: February 4, 2010Applicant: The Regents of the University of CaliforniaInventors: Kathleen M. Giacomini, Joe W. Gray, Anna Lapuk, Shuzhong Zhang